GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pharmigene Inc (ROCO:7595) » Definitions » Debt-to-Revenue

Pharmigene (ROCO:7595) Debt-to-Revenue : 4.50 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pharmigene Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharmigene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$16.8 Mil. Pharmigene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$599.7 Mil. Pharmigene's annualized Revenue for the quarter that ended in Dec. 2024 was NT$137.2 Mil. Pharmigene's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 4.49.


Pharmigene Debt-to-Revenue Historical Data

The historical data trend for Pharmigene's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmigene Debt-to-Revenue Chart

Pharmigene Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial 0.21 0.11 0.07 4.30 5.29

Pharmigene Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 5.31 3.61 6.27 4.50

Competitive Comparison of Pharmigene's Debt-to-Revenue

For the Diagnostics & Research subindustry, Pharmigene's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmigene's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pharmigene's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pharmigene's Debt-to-Revenue falls into.


';

Pharmigene Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharmigene's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(16.792 + 599.694) / 116.534
=5.29

Pharmigene's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(16.792 + 599.694) / 137.156
=4.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.


Pharmigene Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharmigene's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmigene Business Description

Traded in Other Exchanges
N/A
Address
No. 17, Lane 171, Section 2, Jiuzong Road, 4th Floor, Neihu District, Taipei, TWN, 11494
Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.

Pharmigene Headlines

No Headlines